PROTEOMICS, ISSN 1615-9853, 04/2012, Volume 12, Issue 8, pp. 1207 - 1216
Proteolysis represents one of the most tightly controlled physiological processes, as proteases create events that will typically commit pathways in an...
Biomarkers | N‐terminomics | Plasma | Proteases | Technology | TAILS | N-terminomics | BIOCHEMISTRY & MOLECULAR BIOLOGY | BIOCHEMICAL RESEARCH METHODS | PEPTIDASES | PROTEOLYSIS | CLEAVAGE | CANCER | DEGRADOMICS | BIOLOGY | PROTEASE | Amino Acid Sequence | Reference Standards | Peptide Hydrolases - blood | Proteolysis | Humans | Isotope Labeling | Molecular Sequence Data | Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization - methods | Proteome - analysis | Proteomics - methods | Chromatography, Liquid - methods | Peptides - analysis
Biomarkers | N‐terminomics | Plasma | Proteases | Technology | TAILS | N-terminomics | BIOCHEMISTRY & MOLECULAR BIOLOGY | BIOCHEMICAL RESEARCH METHODS | PEPTIDASES | PROTEOLYSIS | CLEAVAGE | CANCER | DEGRADOMICS | BIOLOGY | PROTEASE | Amino Acid Sequence | Reference Standards | Peptide Hydrolases - blood | Proteolysis | Humans | Isotope Labeling | Molecular Sequence Data | Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization - methods | Proteome - analysis | Proteomics - methods | Chromatography, Liquid - methods | Peptides - analysis
Journal Article
Cancer Biology & Therapy, ISSN 1538-4047, 02/2018, Volume 19, Issue 2, pp. 132 - 137
The FDA approved irreversible inhibitor of ERBB1/2/4, neratinib, was recently shown to rapidly down-regulate the expression of ERBB1/2/4 as well as the levels...
neratinib | receptor tyrosine kinase | autophagy | RAS | HDAC | ONCOLOGY | CANCER | ERBB RECEPTORS | Phenylbutyrates - therapeutic use | Proto-Oncogene Proteins p21(ras) - genetics | Humans | Valproic Acid - pharmacology | Quinolines - pharmacology | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Dose-Response Relationship, Drug | Neoplasms - genetics | Phenylbutyrates - pharmacology | Valproic Acid - therapeutic use | Membrane Proteins - metabolism | Receptor, ErbB-2 - antagonists & inhibitors | Drug Evaluation, Preclinical | Proto-Oncogene Proteins p21(ras) - metabolism | ErbB Receptors - antagonists & inhibitors | Membrane Proteins - genetics | Down-Regulation - drug effects | Neoplasms - drug therapy | Drug Synergism | GTP Phosphohydrolases - metabolism | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | GTP Phosphohydrolases - genetics | Autophagy-Related Protein 5 - metabolism | Cell Line, Tumor | Histone Deacetylase Inhibitors - pharmacology | Histone Deacetylase Inhibitors - therapeutic use | Quinolines - therapeutic use | Receptor, ErbB-4 - antagonists & inhibitors | Beclin-1 - metabolism | Neoplasms - pathology
neratinib | receptor tyrosine kinase | autophagy | RAS | HDAC | ONCOLOGY | CANCER | ERBB RECEPTORS | Phenylbutyrates - therapeutic use | Proto-Oncogene Proteins p21(ras) - genetics | Humans | Valproic Acid - pharmacology | Quinolines - pharmacology | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Dose-Response Relationship, Drug | Neoplasms - genetics | Phenylbutyrates - pharmacology | Valproic Acid - therapeutic use | Membrane Proteins - metabolism | Receptor, ErbB-2 - antagonists & inhibitors | Drug Evaluation, Preclinical | Proto-Oncogene Proteins p21(ras) - metabolism | ErbB Receptors - antagonists & inhibitors | Membrane Proteins - genetics | Down-Regulation - drug effects | Neoplasms - drug therapy | Drug Synergism | GTP Phosphohydrolases - metabolism | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | GTP Phosphohydrolases - genetics | Autophagy-Related Protein 5 - metabolism | Cell Line, Tumor | Histone Deacetylase Inhibitors - pharmacology | Histone Deacetylase Inhibitors - therapeutic use | Quinolines - therapeutic use | Receptor, ErbB-4 - antagonists & inhibitors | Beclin-1 - metabolism | Neoplasms - pathology
Journal Article
The Journal of Clinical Pharmacology, ISSN 0091-2700, 1/2012, Volume 52, Issue 1, pp. 55 - 64
Ifosfamide (IFO), which is used in the treatment of pediatric solid tumors, causes high rates of nephrotoxicity. N-acetylcysteine (NAC), an antidote for...
nephrotoxicity | Ifosfamide | children | prevention | N‐acetylcysteine | N-acetylcysteine | METABOLITES | INDUCED FANCONI-SYNDROME | MELATONIN | CYCLOPHOSPHAMIDE | RATS | ANTITUMOR-ACTIVITY | CHLOROACETALDEHYDE | MESNA | children, prevention | ACETAMINOPHEN OVERDOSE | DECHLOROETHYLATION | PHARMACOLOGY & PHARMACY | Rats, Wistar | Area Under Curve | Humans | Male | Protective Agents - therapeutic use | Analgesics, Non-Narcotic - toxicity | Antineoplastic Agents, Alkylating - blood | Female | Acute Kidney Injury - chemically induced | Acetylcysteine - therapeutic use | Ifosfamide - pharmacokinetics | Child | Drug Overdose - drug therapy | Acetaminophen - toxicity | Protective Agents - pharmacokinetics | Ifosfamide - adverse effects | Rats | Antineoplastic Agents, Alkylating - pharmacokinetics | Ifosfamide - blood | Acute Kidney Injury - prevention & control | Animals | Acetylcysteine - blood | Acetylcysteine - pharmacokinetics | Adolescent | Acute Kidney Injury - metabolism | Antineoplastic Agents, Alkylating - adverse effects | Drugs | Prevention | Complications and side effects | Usage | Patient outcomes | Acetylcysteine | Research | Health aspects | Index Medicus
nephrotoxicity | Ifosfamide | children | prevention | N‐acetylcysteine | N-acetylcysteine | METABOLITES | INDUCED FANCONI-SYNDROME | MELATONIN | CYCLOPHOSPHAMIDE | RATS | ANTITUMOR-ACTIVITY | CHLOROACETALDEHYDE | MESNA | children, prevention | ACETAMINOPHEN OVERDOSE | DECHLOROETHYLATION | PHARMACOLOGY & PHARMACY | Rats, Wistar | Area Under Curve | Humans | Male | Protective Agents - therapeutic use | Analgesics, Non-Narcotic - toxicity | Antineoplastic Agents, Alkylating - blood | Female | Acute Kidney Injury - chemically induced | Acetylcysteine - therapeutic use | Ifosfamide - pharmacokinetics | Child | Drug Overdose - drug therapy | Acetaminophen - toxicity | Protective Agents - pharmacokinetics | Ifosfamide - adverse effects | Rats | Antineoplastic Agents, Alkylating - pharmacokinetics | Ifosfamide - blood | Acute Kidney Injury - prevention & control | Animals | Acetylcysteine - blood | Acetylcysteine - pharmacokinetics | Adolescent | Acute Kidney Injury - metabolism | Antineoplastic Agents, Alkylating - adverse effects | Drugs | Prevention | Complications and side effects | Usage | Patient outcomes | Acetylcysteine | Research | Health aspects | Index Medicus
Journal Article
Bioconjugate Chemistry, ISSN 1043-1802, 03/2015, Volume 26, Issue 3, pp. 559 - 571
The mammalian immune system responds to eukaryotic glycan antigens during infections, cancer, and autoimmune disorders, but the immunological bases for such...
REPERTOIRE | PROTEIN | OLIGOSACCHARIDES | GLYCOCONJUGATE VACCINE | BIOCHEMISTRY & MOLECULAR BIOLOGY | BIOCHEMICAL RESEARCH METHODS | CHEMISTRY, ORGANIC | CHEMISTRY, MULTIDISCIPLINARY | IMMUNOGENICITY | INFLUENZAE TYPE-B | CONJUGATE VACCINES | ANTICARBOHYDRATE ANTIBODIES | MICE | POLYSACCHARIDE | Rabbits | Serum Albumin, Bovine - immunology | Mice, Inbred C57BL | Polysaccharides - immunology | Immunity, Cellular - immunology | Glycoproteins - immunology | Animals | Cattle | Oligosaccharides - chemistry | Oligosaccharides - immunology | Polysaccharides - chemistry | Female | Serum Albumin, Bovine - chemistry | Mice | Glycoproteins - chemistry | Glycoconjugate vaccine | derivatized glycans | anti-glycan antibodies | glycan microarrays | lacto-N-neo-tetraose
REPERTOIRE | PROTEIN | OLIGOSACCHARIDES | GLYCOCONJUGATE VACCINE | BIOCHEMISTRY & MOLECULAR BIOLOGY | BIOCHEMICAL RESEARCH METHODS | CHEMISTRY, ORGANIC | CHEMISTRY, MULTIDISCIPLINARY | IMMUNOGENICITY | INFLUENZAE TYPE-B | CONJUGATE VACCINES | ANTICARBOHYDRATE ANTIBODIES | MICE | POLYSACCHARIDE | Rabbits | Serum Albumin, Bovine - immunology | Mice, Inbred C57BL | Polysaccharides - immunology | Immunity, Cellular - immunology | Glycoproteins - immunology | Animals | Cattle | Oligosaccharides - chemistry | Oligosaccharides - immunology | Polysaccharides - chemistry | Female | Serum Albumin, Bovine - chemistry | Mice | Glycoproteins - chemistry | Glycoconjugate vaccine | derivatized glycans | anti-glycan antibodies | glycan microarrays | lacto-N-neo-tetraose
Journal Article
Applied Physics Letters, ISSN 0003-6951, 2014, Volume 104, Issue 8, p. 83502
The cooling effect of field emission from an n-type semiconductor was theoretically investigated in quest for a solid state cooler. The vacuum potential was...
PHYSICS, APPLIED | SELF-ASSEMBLED MONOLAYERS | PERFORMANCE LIMITS | GATE DIELECTRICS | DEPOSITION | HIGH-QUALITY | THIN-FILM TRANSISTORS | GRAPHENE TRANSISTORS | CURRENT SATURATION | MULTILAYERS | MOLECULES | Exchanging | Cooling | Emission analysis | Cooling effects | N-type semiconductors | Field emission | Electron emission | Configurations | Cathodes | ELECTRON EMISSION | CATHODES | TEMPERATURE RANGE 0400-1000 K | CONFIGURATION | CURRENT DENSITY | CONDENSED MATTER PHYSICS, SUPERCONDUCTIVITY AND SUPERFLUIDITY | ENERGY TRANSFER | COOLING | N-TYPE CONDUCTORS | POWER DENSITY | FIELD EMISSION | SEMICONDUCTOR MATERIALS | GEOMETRY
PHYSICS, APPLIED | SELF-ASSEMBLED MONOLAYERS | PERFORMANCE LIMITS | GATE DIELECTRICS | DEPOSITION | HIGH-QUALITY | THIN-FILM TRANSISTORS | GRAPHENE TRANSISTORS | CURRENT SATURATION | MULTILAYERS | MOLECULES | Exchanging | Cooling | Emission analysis | Cooling effects | N-type semiconductors | Field emission | Electron emission | Configurations | Cathodes | ELECTRON EMISSION | CATHODES | TEMPERATURE RANGE 0400-1000 K | CONFIGURATION | CURRENT DENSITY | CONDENSED MATTER PHYSICS, SUPERCONDUCTIVITY AND SUPERFLUIDITY | ENERGY TRANSFER | COOLING | N-TYPE CONDUCTORS | POWER DENSITY | FIELD EMISSION | SEMICONDUCTOR MATERIALS | GEOMETRY
Journal Article
Classical and Quantum Gravity, ISSN 0264-9381, 04/2015, Volume 32, Issue 7, pp. 74001 - 74041
The Advanced LIGO gravitational wave detectors are second-generation instruments designed and built for the two LIGO observatories in Hanford, WA and...
interferometers | gravitational waves | optics | seismic isolation | QUANTUM SCIENCE & TECHNOLOGY | MECHANICAL LOSS | PHYSICS, MULTIDISCIPLINARY | READOUT | RADIATION | ALIGNMENT | ASTRONOMY & ASTROPHYSICS | FREQUENCY | GRAVITATIONAL-WAVE DETECTOR | PHYSICS, PARTICLES & FIELDS | Design for recycling | Lasers | Gravitational waves | Detectors | Recycling | Quantum gravity | Gain | Interferometers
interferometers | gravitational waves | optics | seismic isolation | QUANTUM SCIENCE & TECHNOLOGY | MECHANICAL LOSS | PHYSICS, MULTIDISCIPLINARY | READOUT | RADIATION | ALIGNMENT | ASTRONOMY & ASTROPHYSICS | FREQUENCY | GRAVITATIONAL-WAVE DETECTOR | PHYSICS, PARTICLES & FIELDS | Design for recycling | Lasers | Gravitational waves | Detectors | Recycling | Quantum gravity | Gain | Interferometers
Journal Article
Nature Physics, ISSN 1745-2473, 2011, Volume 7, Issue 12, pp. 962 - 965
Around the globe several observatories are seeking the first direct detection of gravitational waves (GWs). These waves are predicted by Einstein's general...
PHYSICS, MULTIDISCIPLINARY | SQUEEZED STATES | DETECTOR | Optics | Astrophysics | Black holes | Quantum physics | Particle physics | Observatories | Lasers | Gravitational waves | Fluctuation | Detectors | Electromagnetic fields | Astronomy | Interferometers
PHYSICS, MULTIDISCIPLINARY | SQUEEZED STATES | DETECTOR | Optics | Astrophysics | Black holes | Quantum physics | Particle physics | Observatories | Lasers | Gravitational waves | Fluctuation | Detectors | Electromagnetic fields | Astronomy | Interferometers
Journal Article
American Journal of Kidney Diseases, ISSN 0272-6386, 2010, Volume 56, Issue 4, pp. 643 - 650
Background Evidence for a protective effect of N -acetylcysteine (NAC) on acute and chronic kidney disease is equivocal, and controversy persists about whether...
Nephrology | cystatin C, N-acetylcysteine | Chronic kidney disease | creatinine clearance | urine protein | serum creatinine | CLEARANCE | PREVENTION | INJURY | PREDICTION | PROTECTS | ANGIOGRAPHY | DISEASE | UROLOGY & NEPHROLOGY | GLOMERULAR-FILTRATION RATE | CONTRAST-INDUCED NEPHROPATHY | CHRONIC-RENAL-FAILURE | Severity of Illness Index | Confidence Intervals | Kidney Failure, Chronic - diagnosis | Double-Blind Method | Drug Administration Schedule | Follow-Up Studies | Risk Assessment | Administration, Oral | Humans | Kidney Failure, Chronic - drug therapy | Middle Aged | Male | Reference Values | Treatment Outcome | Kidney Function Tests | Dose-Response Relationship, Drug | Cystatin C - analysis | Statistics, Nonparametric | Aged, 80 and over | Creatinine - blood | Female | Aged | Acetylcysteine - therapeutic use
Nephrology | cystatin C, N-acetylcysteine | Chronic kidney disease | creatinine clearance | urine protein | serum creatinine | CLEARANCE | PREVENTION | INJURY | PREDICTION | PROTECTS | ANGIOGRAPHY | DISEASE | UROLOGY & NEPHROLOGY | GLOMERULAR-FILTRATION RATE | CONTRAST-INDUCED NEPHROPATHY | CHRONIC-RENAL-FAILURE | Severity of Illness Index | Confidence Intervals | Kidney Failure, Chronic - diagnosis | Double-Blind Method | Drug Administration Schedule | Follow-Up Studies | Risk Assessment | Administration, Oral | Humans | Kidney Failure, Chronic - drug therapy | Middle Aged | Male | Reference Values | Treatment Outcome | Kidney Function Tests | Dose-Response Relationship, Drug | Cystatin C - analysis | Statistics, Nonparametric | Aged, 80 and over | Creatinine - blood | Female | Aged | Acetylcysteine - therapeutic use
Journal Article
Bioorganic and Medicinal Chemistry, ISSN 0968-0896, 01/2012, Volume 20, Issue 2, pp. 1008 - 1019
We have developed efficient methods for the preparation of N ,5′-bis-ureidoadenosine derivatives and their 5′-carbamoyl-N -ureido congeners. Treatment of...
5′-Bis-ureidoadenosines | Antiproliferative activity | BMPR1b | Anticancer nucleosides | APOPTOSIS | DESIGN | CHEMISTRY, MEDICINAL | CANCER CELLS | ACTIVE-SITE | BIOCHEMISTRY & MOLECULAR BIOLOGY | ID PROTEINS | CHEMISTRY, ORGANIC | CELL-CYCLE ARREST | CYTOTOXIC NUCLEOSIDE ANALOGS | N-6,5 '-Bis-ureidoadenosines | HIV-1 REVERSE-TRANSCRIPTASE | INHIBITORS | BINDING
5′-Bis-ureidoadenosines | Antiproliferative activity | BMPR1b | Anticancer nucleosides | APOPTOSIS | DESIGN | CHEMISTRY, MEDICINAL | CANCER CELLS | ACTIVE-SITE | BIOCHEMISTRY & MOLECULAR BIOLOGY | ID PROTEINS | CHEMISTRY, ORGANIC | CELL-CYCLE ARREST | CYTOTOXIC NUCLEOSIDE ANALOGS | N-6,5 '-Bis-ureidoadenosines | HIV-1 REVERSE-TRANSCRIPTASE | INHIBITORS | BINDING
Journal Article
HOMOLOGY HOMOTOPY AND APPLICATIONS, ISSN 1532-0073, 2018, Volume 20, Issue 1, pp. 5 - 36
The homotopy types of U (n)-gauge groups over the two most fundamental 4-manifolds S-4 and CP2 are studied. We give homotopy decompositions of the U (n)-gauge...
gauge group | MATHEMATICS | homotopy type | MATHEMATICS, APPLIED | homotopy decomposition | GAUGE GROUPS | EVALUATION MAP | function space | MODULI SPACES | SURFACES
gauge group | MATHEMATICS | homotopy type | MATHEMATICS, APPLIED | homotopy decomposition | GAUGE GROUPS | EVALUATION MAP | function space | MODULI SPACES | SURFACES
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2008, Volume 358, Issue 24, pp. 2545 - 2559
Intensive glucose lowering targeting glycated hemoglobin levels of less than 6.0% was unexpectedly associated with an increase in overall mortality in...
TRIAL | MEDICINE, GENERAL & INTERNAL | GLYCEMIC CONTROL | DESIGN | RATIONALE | CONTROL CARDIOVASCULAR RISK | DISEASE | PREVENTION | COMPLICATIONS | MELLITUS | ASSOCIATION | Glycated Hemoglobin A - analysis | Blood Glucose - analysis | Follow-Up Studies | Humans | Middle Aged | Kaplan-Meier Estimate | Proportional Hazards Models | Hypertension - drug therapy | Male | Cardiovascular Diseases - complications | Diabetes Mellitus, Type 2 - blood | Hypoglycemic Agents - administration & dosage | Diabetes Mellitus, Type 2 - mortality | Treatment Failure | Cardiovascular Diseases - epidemiology | Hypertension - complications | Adult | Female | Aged | Diabetes Mellitus, Type 2 - drug therapy | Drug Therapy, Combination | Hypoglycemia - chemically induced | Hypoglycemic Agents - adverse effects | Diabetes Mellitus, Type 2 - complications | Type 2 diabetes | Evaluation | Care and treatment | Cardiovascular diseases | Blood sugar | Risk factors | Hyperglycemia | Hypotheses | Mortality | Cardiovascular disease | Diabetes | Glucose | Metabolic disorders | Index Medicus | Abridged Index Medicus
TRIAL | MEDICINE, GENERAL & INTERNAL | GLYCEMIC CONTROL | DESIGN | RATIONALE | CONTROL CARDIOVASCULAR RISK | DISEASE | PREVENTION | COMPLICATIONS | MELLITUS | ASSOCIATION | Glycated Hemoglobin A - analysis | Blood Glucose - analysis | Follow-Up Studies | Humans | Middle Aged | Kaplan-Meier Estimate | Proportional Hazards Models | Hypertension - drug therapy | Male | Cardiovascular Diseases - complications | Diabetes Mellitus, Type 2 - blood | Hypoglycemic Agents - administration & dosage | Diabetes Mellitus, Type 2 - mortality | Treatment Failure | Cardiovascular Diseases - epidemiology | Hypertension - complications | Adult | Female | Aged | Diabetes Mellitus, Type 2 - drug therapy | Drug Therapy, Combination | Hypoglycemia - chemically induced | Hypoglycemic Agents - adverse effects | Diabetes Mellitus, Type 2 - complications | Type 2 diabetes | Evaluation | Care and treatment | Cardiovascular diseases | Blood sugar | Risk factors | Hyperglycemia | Hypotheses | Mortality | Cardiovascular disease | Diabetes | Glucose | Metabolic disorders | Index Medicus | Abridged Index Medicus
Journal Article